期刊文献+

肾移植术后低剂量与常规剂量环孢素A比较进行免疫抑制治疗有效性与安全性的Meta分析 被引量:3

Low-Dose and Standard-dose Cyclosporine Immunosuppressive Therapy in Kidney Transplant Recipients:A Meta-analysis of Effectiveness and Safety
下载PDF
导出
摘要 目的系统评价肾移植术后环孢素A低剂量与常规剂量比较的免疫抑制效果和安全性。方法计算机检索MEDLINE、EMbase、SCI、CBM、Cochrane图书馆检索时间均从建库至2009年12月,纳入肾移植术后环孢素A低剂量与常规剂量比较进行免疫抑制治疗的随机对照试验(RCT)。在评价纳入研究的方法学质量和提取有效数据后,采用RevMan5.0进行Meta分析。结果共纳入6个RCT,包括1551例患者,质量评价结果显示4个研究为A级、2个为B级。Meta分析结果显示:随访6个月及12个月两组急性排斥反应发生率[RR=1.07,95%CI(0.69,1.65);RR=1.06,95%CI(0.71,1.57)]、受者病死率[RR=0.64,95%CI(0.20,2.03);RR=0.61,95%CI(0.30,1.24)];以及移植物丢失率[RR=0.72,95%CI(0.38,1.36);RR=0.82,95%CI(0.54,1.25)]差异均无统计学意义,肾脏功能及纳入分析的安全性指标差异均无统计学意义。结论基于当前临床证据,肾移植术后CsA低剂量与常规剂量相比,近期疗效和安全性相似;远期结果有待进一步研究探讨。 Objective To evaluate the efficacy and safety of low-dose versus standard-dose cyclosporine immunosuppressive therapy in kidney transplant recipients.Methods We searched MEDLINE,EMbase,SCI,CBM and The Cochrane Library from the establishment to December 2009 to screen randomized controlled trials(RCTs) of low-dose versus standard-dose cyclosporine immunosuppressive therapy in kidney transplant recipients.Quality assessment and metaanalyses were performed for the included studies.Results A total of 6 RCTs involving 1551 patients were identified,among which 4 RCTs were graded A and two were graded B.The meta-analyses indicated that there were no significant differences between the two groups at the end of 6-month and 12-month follow-up in the acute rejection rate at a RR 1.07,95%CI 0.69 to 1.65 and a RR 1.06,95%CI 0.71 to 1.57,respectively.There were no signif icant differences between the two groups at the end of 6-month and 12-month follow-up in the patients' death rate at a RR 0.64,95%CI 0.20 to 2.03 and a RR 0.61,95%CI 0.30 to 1.24,respectively.There were no signif icant differences between the two groups in renal function and safety.Conclusion Based on the current evidence,compared with standard-dose CsA,low-dose CsA has the same effect and safety for the short-term results,but the long-term results need to be further studied.
出处 《中国循证医学杂志》 CSCD 2010年第6期683-687,共5页 Chinese Journal of Evidence-based Medicine
关键词 环孢素A 剂量 肾移植 META分析 Cyclosporine Dosage Kidney transplantation Meta-analysis
  • 相关文献

参考文献11

  • 1Sutherland DE,Gores PF,Farney AC,et al.Evolution of kidney,pancreas,and islet transplantation for patients with diabetes at the University of Minnesota.Am J Surg,1993,166(5):456-491.
  • 2Srinivas TR,Meier-Kriesche HU.Minimizing immunosuppression,an alternative approach to reducing side effects:objectives and interim result.Clin J Am Soc Nephrol,2008,3(2Suppl):S101-116.
  • 3Ghafari A,Makhdoomi K,Ahmadpour P,et al.Low-dose versus high-dose cyclosporine induction protocols in renal transplantation.Transplantation Proceedings,2007,39(4):1219-1222.
  • 4Ekberg H,Tedesco-Silva H,Demirbas A,et al.Reduced exposure to calcineurin inhibitors in renal transplantation.N Engl J Med,2007,357(25):2562-2575.
  • 5Cibrik D,Meier-Kriesche HU,Bresnahan B,et al.Renal function with cyclosporine C2 monitoring,enteric-coated mycophenolate sodium and basiliximab:a 12-month randomized trial in renal transplant recipients.Clinical Transplantation,2007,21(2):192-201.
  • 6Mulgaonkar S,Tedesco H,Oppenheimer F,et al.FTY720/cyclosporine regimens in de novo renal transplantation:a 1-year dosefinding study.Am J Transplant,2006,6(8):1848-1857.
  • 7de Sevaux RG,Gregoor PJ,Hene RJ,et al.A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids.J Am Soc Nephrol,2001,12(8):1750-1757.
  • 8Brady HR,Kamel KS,Harding ME,et al.Low dose ciclosporin from the early postoperative period yields potent immunosuppression after renal transplantation.Nephron,1990,55(4):394-399.
  • 9Burdmann EA,Andoh TF,Yu L,et al.Cydosporine nephrotoxicity.Semin Nephrol,2003,23(5):465-476.
  • 10吴斌,吴逢波,于磊,李天平,唐尧.基于TOR-I的CNI撤除方案在肾移植术后免疫抑制治疗中疗效和安全性的Meta分析[J].中国循证医学杂志,2010,10(1):33-39. 被引量:1

二级参考文献20

  • 1de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am JKidney Dis, 2000, 35(2): 333-346.
  • 2Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev, 2006, 19(2): CD004290.
  • 3Mulay AV, Hussain N, Fergusson D, et al. Calcineurin Inhibitor Withdrawal from Sirolimus-Based Therapy in Kidney Transplantation: A Systematic Review of Randomized Trials. Am J Transplant, 2005, 5(7): 1748-1756.
  • 4Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation, 2001, 72(5): 777-786.
  • 5Oberbauer R, Kreis H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation, 2003, 76(2): 364-370.
  • 6Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am SocNephrol, 2004, 15(3): 809-817.
  • 7Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transl)l Int, 2005, 18 ( 1 ): 22-28.
  • 8Gonwa TA, Hricik DE, Brinker K, et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation, 2002, 74(11): 1560-1567.
  • 9Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation, 2003, 75(8): 1404-1408.
  • 10Stallone G, Di Paolo S, Schena A, et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation, 2003, 75(7): 998-1003.

同被引文献32

  • 1廖燚,王新玲,吴泰相.扩髓与非扩髓髓内钉固定治疗股骨干骨折的系统评价[J].中国循证医学杂志,2004,4(9):620-626. 被引量:5
  • 2Ratilal B,Costa J,Sampaio C,陈耀龙(译),刁骧(审校).颅底骨折患者预防性使用抗生素预防脑膜炎的系统评价(英文)[J].中国循证医学杂志,2006,6(8):576-585. 被引量:7
  • 3王苟思义,张雷.免疫抑制剂在移植领域中的应用进展[J].中国医师进修杂志(外科版),2006,29(9):70-72. 被引量:2
  • 4许风雷,环文英,吴泰相,邱霞,张红,刘新华.冬虫夏草治疗慢性肾病临床疗效的系统评价[J].中国循证医学杂志,2006,6(11):804-808. 被引量:13
  • 5Sutherland DE, Gores PF, Farney AC, et al. Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota[J]. Am J Surg, 1993, 166(5):456- 491.
  • 6Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta analysis and meta-regression of randomised trial data[J]. BMJ, 2005, 331(7520) :810.
  • 7Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm[J]. Clin J Am Soc Nephrol, 2009, 4(12) :2029-2034.
  • 8Hailer M, Oberbauer R. Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation [J]. Transpl Int, 2009, 22(1):69- 77.
  • 9Juni P, Altman DG, Eger M. Assessing the quality of controlled clinical trails[J]. BMJ, 2001, 323:42-46.
  • 10Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 0. 1 [DB]. The Cochrane Collaboration, 2008. Available at:www. coehranehandbook. org.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部